PAREXEL

Why PAREXEL®?

To meet the demands of a challenging global marketplace, biopharmaceutical companies of all sizes are embracing strategic partnerships to create a cost-efficient blend of internal and external resources that helps them optimize their development programs and product portfolios.  This new approach allows biopharmaceutical companies to reduce oversight costs and concentrate on their highest priorities – such as research, product acquisition, and market expansion. Benefits can include significant cost savings, accelerated product development, higher quality, and reduced risk.  To capitalize on those benefits, however, a biopharmaceutical company must choose the right partner – one with in-depth experience, proven processes, a global infrastructure, and a complete range of biopharmaceutical services that are fully enabled by technology.

A unique combination of expertise, resources and technology

PAREXEL is the only biopharmaceutical services provider offering a comprehensive global network of expertise, clinical resources, and technology within a single organization – a unique combination that maximizes your product development efficiency. Whatever your requirements, delivering proven, integrated solutions across every phase of the product lifecycle… every therapeutic area… and every geographic region. Our unsurpassed qualifications include:

• Conducting studies in more than 100 countries
• Full range of services in every phase of development
• Scientific and medical expertise across all major therapeutic areas
• Advanced proprietary eClinical technologies
• Clinical and regulatory strategists encompassing the complete development cycle
• Access to emerging markets

As an innovator in the biopharmaceutical services industry, PAREXEL continues to create new models of operating excellence and best practices to help our industry partners address key product development challenges. The proven benefits of PAREXEL’s integrated approach include:

Cost savings – Reduced sponsor oversight, faster study start-up and closeout, and improved study management

Accelerated development times – Faster patient recruitment, better site selection, and integrated technology

Risk mitigation – Improved data reliability, proven protocols, and greater focus on first-cycle approvals

Quality optimization – Standardized processes, improved training, and reduced data redundancy

These benefits can cut the cost of a typical Phase III trial by 10-15 percent – savings that are worth millions of dollars at a time when cost reductions and accelerated development times are absolutely vital for success in the biopharmaceutical marketplace.

By selecting PAREXEL as your strategic partner, your company can leverage our dedication, expertise, innovative technology, and global infrastructure to accelerate completion of key development milestones, increase efficiency, and reduce the cost of bringing new products to market.  Most important, only PAREXEL has the experience, flexibility and resources to provide the right combination of biopharmaceutical services and technology for any product development requirement – making us the right partner for today’s difficult global environment.